Yahoo! News Story - Patient Groups Take Stock of State of Stem Cell Research One Year Later; CAMR Calls for Bush's Help in Fully Implementing Policy

August 5, 2002

Werre (b.werre@...) has sent you a news article

Personal message:

Hi all,Interesting note on stem cell research. Take care, Bill Werre

Patient Groups Take Stock of State of Stem Cell Research One Year Later; CAMR Calls for Bush's Help in Fully Implementing Policy

http://story.news.yahoo.com/news?tmpl=story&u=/020805/180/1zbry.html

News Home - Yahoo! - Help

Welcome, Guest

Personalize News Home Page

-

Sign In

Yahoo! News

Monday, August 05, 2002

Search

News Front Page

Most Popular

Audio/Video

Full Coverage

Lottery

Crosswords

News Resources

Providers

U.S. Newswire

News Alerts

National Institutes of Health

Department of Health and Human Services

National Academy of Sciences

President Bush

Politics - U.S. Newswire Press Releases

Patient Groups Take Stock of State of Stem Cell Research One Year Later; CAMR Calls for Bush's Help in Fully Implementing Policy

Mon Aug 5,11:00 AM ET

To: National Desk, Health Reporter

Contact: Kimbrough, , or Maggie Goldberg, , ext. 115, both of the Coalition for the Advancement of Medical Research

WASHINGTON, Aug. 5 /U.S. Newswire/ -- One year after President Bush (

news -

web sites) announced his decision on whether or not to allow federal funding for embryonic stem cell research, the Coalition for the Advancement of Medical Research (CAMR) examined the state of the research -- the successes achieved in implementing the President's policy and the major challenges that remain-and proposed potential solutions. In a letter to the President, CAMR will call on the Administration to meet with leading stem cell researchers, cell line owners, and patient groups so that the obstacles to implementing the policy can be addressed. CAMR, comprised of leading patient groups, universities, and scientific societies, led the charge to support federal funding of stem cell research and has led the efforts opposing a ban on therapeutic cloning.

"When President Bush announced his decision on federal funding for embryonic stem cell research on August 9, 2001, we expressed concern that while we believed some research could be carried out on the limited cell lines available, the policy was too limited over the long-term to successfully move embryonic stem cell research forward," said Manganiello, president of CAMR.

"One year later, we can say that there has been some good research under the policy, the promise of stem cell research continues to be proven every day, and good faith efforts have been made in implementing the President's policy.

However, we still do not have the 60 cell lines promised, only 17 (footnote) are available for researchers, and we believe that only one line owner is actually sharing its line with research labs. The Administration has not created a sufficiently positive environment for embryonic stem cell research to flourish, nor have they been as aggressive in implementing their policy as they should have been. The political climate surrounding stem cell research has steered many scientists away from pursuing the research and many companies away from investing in it -- this only further delays vital cures for patients," added Manganiello.

Some of the successes in implementing the President's policy over the past year include:

-- The National Institutes of Health (

news -

web sites) (NIH) has developed the Stem Cell Registry, initiated support for 13 administrative supplements for embryonic stem cell research, issued a program for "Career Enhancement Awards" as well as a program to help researchers with stem cell research techniques, negotiated four material transfer agreements for NIH intramural investigators to obtain access to human embryonic cell lines, and issued numerous program announcements and requests for proposals.

-- The Department of Health and Human Services (

news -

web sites) (HHS) has been helpful in clearing administrative red tape so that the NIH's implementation activities can proceed, and Secretary in particular has played a critical role in urging private owners to share lines. A few stem cell lines holders have signed agreements with the NIH, and one in particular, WARF/WiCell has shared its line with researchers more than fifty times already. In addition, universities are beginning to develop institutional policies and plans on embryonic stem cell research.

However, some of the critical challenges that remain are:

-- The number of stem cell lines available, only 17 (footnote), is far less than the 60 originally promised.

-- The NIH still does not have full information up for many lines on the Stem Cell Registry, its promised funding targets are far from being met, and most stem cell lines holders have not signed agreements with the Department.

-- The number of stem cell research applications is less than expected as some researchers may be concerned about entering the field due to visibility and/or potential difficulty in obtaining embryonic stem cell lines.

-- The focus of HHS on embryonic stem cell research policy implementation was diverted by the very necessary response to events of September 11, but it has never fully regained momentum. This has led the Department to have difficulty aggressively implementing the Administration's policy and in maintaining pressure on more than a few stem cell line-owners, especially foreign owners.

-- Congress has also provided less oversight post-September 11 and more is needed on the Administration and stem cell line holders.

-- University planning has been slower than expected and the political climate at the state level is hindering some universities from entering the stem cell research field.

In a letter to the President, CAMR will propose the following solutions:

-- The President should call for a meeting to review the state of embryonic stem cell research, which would include as participants our nation's leading embryonic stem cell researchers, university and industry representatives, federal research agency leaders, stem cell line owners, and patient groups to hear first-hand the successes achieved, the problems that remain with implementation, and to discuss ways to speed the process.

-- The NIH should work with the American Society for Cell Biology (ASCB) and other relevant parties to determine what information is needed for the registry, demand such information from line owners, and post such information on the Web site expeditiously.

-- The NIH should also hold a stem cell research workshop for scientists in the field to promote the availability of funding support for additional grantees; convene a National Academy of Sciences (

news -

web sites) (NAS) panel to solicit recommendations on whether scientific needs require a modification to current federal policy; and encourage additional private investment in stem cell research and additional derivation.

-- Secretary should meet with any stem cell line holder which has not yet shared its lines to work out appropriate terms that encourage them to share.

-- The Secretary should also call for a meeting between the NIH and research advocates to discuss implementation issues and prioritize needed responses; organize a working group with representatives from other departments, including State and Commerce, to discuss ways to encourage transfer of foreign stem cell lines to U.S. researchers; and use his position and stature to promote a more positive research environment, encourage resolution of intellectual property issues, and increased sharing of cell lines.

-- Congress should hold hearings on oversight and other major issues, introduce legislation or provide resources if needed to remedy obstacles, and hear directly from stem cell line holders.

-- Scientific societies and research universities should promote the availability of federal funding and encourage applications for grants.

"In the end this all comes back to the 100 million Americans suffering from life-threatening diseases and conditions who could be helped from advances in embryonic stem cell research. The stakes are high, and the potential benefits could mean the difference between life and death for the families we represent," added Manganiello.

Footnote: We believe there are 17 lines currently available though estimates range from 5 to 24.

The Coalition for the Advancement of Medical Research (CAMR), is comprised of nationally-recognized patient organizations, universities, scientific societies, foundations, and individuals with life-threatening illnesses and disorders, advocating for the advancement of breakthrough research and technologies in regenerative medicine -- including stem cell research and somatic cell nuclear transfer -- in order to cure disease and alleviate suffering. For more information on CAMR, visit the Web site:

http://www.camradvocacy.org

http://www.usnewswire.com/

-0-

Print Story

Next Story >

Message Boards: Post/Read Msgs

Sign In

Yahoo! News Story - Patient Groups Take Stock of State of Stem Cell Research One Year Later; CAMR Calls for Bush's Help in Fully Implementing Policy

Recommended Posts

Guest guest

Link to comment

Share on other sites

Join the conversation

Activity